CSL, the parent company of CSL Behring, announced a reported net profit after tax of $2.91 billion1,2. This is a profit increase of 11% at constant currency (CC)² versus the previous year and thus exceeds the forecasts for the 2024 financial year.
This result reflects:
-
Our largest franchise, the immunoglobulins portfolio, delivered exceptional growth driven by significant patient demand and the recovery in CSL Behring’s gross margin is progressing to plan.
-
The momentum in plasma collections has continued and the cost per litre. Significant progress has been made on digital transformation with an enhanced focus on plasma centre efficiencies.
-
CSL Vifor continues to grow iron volume in Europe despite generic entrants and we remain confident in our plan to drive long-term value from this business.
-
CSL Seqirus outperformed the market in a challenging environment driven by the adjuvanted influenza vaccine FLUAD®.
Dr Paul McKenzie, CSL’s Chief Executive Officer and Managing Director said, “Overall, this result demonstrates that we are delivering on the strategic objectives that we communicated at our Capital Markets Day in October last year. We remain confident in our double-digit earnings growth target over the medium-term, reflecting a disciplined focus on the execution of our strategy.”
Read about our CSL 2023/2024 Financial Results as well as the full ASX announcement including operational highlights and outlook on CSL.com.
1All figures are expressed in US dollars unless otherwise stated.
2 Constant currency (CC) removes the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to CSL’s Financial Statements for the Full Year ended June 2024 (Directors’ Report).
